In this phase @ trial , we randomly assigned @ adults with newly diagnosed mantle-cell lymphoma who were ineligible or not considered for stem-cell transplantation to receive six to eight @-day cycles of R-CHOP intravenously on day @ ( with prednisone administered orally on days @ to @ ) or VR-CAP ( R-CHOP regimen , but replacing vincristine with bortezomib at a dose of @ mg per square meter of body-surface area on days @ , @ , @ , and @ ) .